Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AVARA Rx vs Primary Clinic (Direct GLP)

AVARA Rx
Graded #267

Lower grade

vs+5.900000000000006
Primary Clinic (Direct GLP)
Graded #145

Higher grade

The verdict

Primary Clinic (Direct GLP) takes it — 68.7/100 to 62.8/100.

Primary Clinic (Direct GLP) grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Primary Clinic (Direct GLP) is a Direct Primary Care membership rather than the usual direct-to-consumer GLP-1 marketplace.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuePrimary Clinic (Direct GLP) +35
43
78
Dose & formulationAVARA Rx +23
77
54
Clinical oversightAVARA Rx +1
76
75
Labs & monitoringPrimary Clinic (Direct GLP) +24
52
76
FulfillmentAVARA Rx +4
77
73
Contract termsAVARA Rx +14
55
41
AVARA Rx · left barPrimary Clinic (Direct GLP) · right bar

The numbers

MetricAVARA RxPrimary Clinic (Direct GLP)
WeighScore62.8/10068.7/100
GradeCC
Scorecard rank#267#145
Semaglutide$229/mo (starting dose, compounded)$65/mo (0.25 mg dose, promotional rate, compounded)
Tirzepatide$279/mo (starting dose, compounded)$110/mo (2.5 mg dose, promotional rate, compounded)
CoverageAll 50 states10 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
AVARA Rx

Graded #267 · C

Strengths

  • Names its pharmacy partner (DiRx Health, Ft Lauderdale FL) — buyers can independently verify its licensure
  • Names its clinical network (Beluga Health) — you can research the platform handling your prescriptions
  • All 50 states explicitly listed on the FAQ — uncommon vs peers that just say 'nationwide'
  • Patient-friendly refunds — full refund if a provider disqualifies you, partial if a weaker dose is prescribed
  • LegitScript verification badge displayed; pharmacy claims NABP-accredited facilities

Where it loses points

  • Operating legal entity not disclosed — only a Sheridan, WY registered-agent-style address surfaced
  • Dose pricing not itemized — only 'starting at $229' semaglutide and 'starting at $279' tirzepatide
  • LegitScript certification number not shown — badge only, so no direct lookup
  • No named medical director (Beluga Health is the network, not a named MD)
  • Lab work requirements not specified, and consultation fee not broken out from medication cost

Strengths

  • Direct Primary Care model integrates GLP-1 with continuous primary care — unlike most direct-to-consumer platforms
  • GLP-1 at wholesale cost with no markup — semaglutide from $65/mo, tirzepatide from $110/mo (members only)
  • Unlimited primary care visits, direct text access, and same-day care bundled in the $89/mo membership
  • Routine labs and thousands of medications included in membership — no surprise bills
  • Per-dose pricing shown publicly for all 8 dose tiers of both semaglutide and tirzepatide

Where it loses points

  • 10 states only (WA, NM, AZ, UT, FL, DC, KS, OK, VA, GA) — limited vs 50-state platforms
  • Membership required to access wholesale pricing — $89/mo adds ~$1,068/yr in fixed cost
  • 503A pharmacy partners not named
  • LegitScript certification not mentioned on the site
  • Medical director and corporate legal entity not disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard